18.
Other (Charges) Gains, Net
## Table 0 ##
2014 During the year ended December 31, 2014, the Company received consideration of $8 million in connection with the settlement of a claim against a bankrupt supplier.
The Company also recorded $12 million of damages in connection with the settlement of a claim by a raw materials supplier.
These commercial dispute resolutions are included in the Acetyl Intermediates segment.
In addition, the Company recovered $15 million from an arbitration award against a former utility operator at its cellulose derivatives manufacturing facility in Narrows, Virginia, which is included in the Consumer Specialties segment.
During the year ended December 31, 2014 the Company recorded $4 million of employee termination benefits related to the closure of its acetic anhydride facility in Roussillon, France and its VAM facility in Tarragona, Spain (Note 4).
In addition, the Company recorded $2 million of contract termination adjustments related to the closure of its VAM facility in Tarragona, Spain (Note 4).2013 During the three months ended December 31, 2013, the Company recorded $6 million of employee termination benefits, $3 million of contract termination costs and $3 million of long-lived asset impairment losses related to the December 2013 closure of its acetic anhydride facility in Roussillon, France.
In addition, the Company recorded $14 million of employee termination benefits, $30 million of contract termination costs and $31 million of long-lived asset impairment losses as a result of the December 2013 closure of its VAM facility in Tarragona, Spain.
The long-lived asset impairment losses related to both the Company's Roussillon acetic anhydride facility and Tarragona VAM facility were measured at the dates of impairment to fully write-off the related property, plant and equipment at both facilities (Note 2 and Note 4).
During the three months ended December 31, 2013, the Company determined its Singapore acetic acid production unit should be assessed for impairment based on local market conditions affecting demand for acetic acid and downstream products, the cost to operate the unit, contractual obligations and an interim arbitration ruling (Note 24).
As a result, the Company concluded that the long-lived assets at its Singapore acetic acid production unit were fully impaired.
Accordingly, the Company recorded long-lived asset impairment losses, measured at the date of impairment, of $46 million to fully write-off the related property, plant and equipment.
The Singapore acetic acid operations are included in the Acetyl Intermediates segment (Note 2).2012 During the year ended December 31, 2012, the Company recorded $5 million of employee termination benefits, related to the closure of the Company's acetate flake and acetate tow manufacturing operations at its Spondon, Derby, United Kingdom site.
Also during the year ended December 31, 2012, the Company concluded that certain long-lived assets were partially impaired at its acetate flake and acetate tow manufacturing operations in Spondon, Derby, United Kingdom.
Accordingly, the Company wrote down the related property, plant and equipment to its fair value of $3 million, measured at the date of impairment, resulting in long-lived asset impairment losses of $8 million for the year ended December 31, 2012 (Note 2).
Business Segments Advanced Engineered Materials
## Table 1 ##
Our Advanced Engineered Materials segment includes our engineered materials business and certain strategic affiliates.
Our engineered materials business develops, produces and supplies a broad portfolio of high performance specialty polymers for automotive and medical applications, as well as industrial products and consumer electronics.
Together with our strategic affiliates, our engineered materials business is a leading participant in the global specialty polymers industry.
The primary products of Advanced Engineered Materials are polyoxymethylene, also commonly known as POM, Ultra-high molecular weight polyethylene ("UHMW-PE"), polybutylene terephthalate ("PBT"), long-fiber reinforced thermoplastics ("LFRT") and liquid crystal polymers ("LCP").
POM, LFRT and PBT are used in automotive and medical applications as well as consumer electronics, appliances and industrial products.
UHMW-PE, sold under the GUR ?
trademark, is used in battery separators, conveyor belts, filtration equipment, coatings and medical applications.
Primary end uses for LCP are electrical applications or products and consumer electronics.
PPS, sold under the Fortron ?
brand, is a key product of Fortron Industries LLC, one of our strategic affiliates.
PPS is used in a wide variety of automotive and other applications, especially those requiring heat and/or chemical resistance.
Year Ended December 31, 2014 Compared with Year Ended December 31, 2013 Advanced Engineered Materials' net sales increased $107 million, or 7.9%, for the year ended December 31, 2014 compared to the same period in 2013 primarily due to higher volume globally, partially offset by lower pricing for POM and GUR ?
due to shifts in product and geographic sales mix.
In Europe, volume increased due to strong growth in nearly all product lines.
Volume in the Americas increased primarily driven by growth in POM in automotive applications and GUR ?
in medical and industrial applications.
In Asia, volume increased across all product lines resulting from targeted customer focus and the implementation of growth strategies.
Operating profit decreased $683 million, or 75.6%, for the year ended December 31, 2014 compared to the same period in 2013 primarily driven by the recognition of a gain of $742 million during the three months ended December 31, 2013, which represents the deferred proceeds in excess of divested assets as a result of the 2006 settlement agreement with Fraport to move our German POM operations.
Lower pricing, a $16 million negative impact from inventory build in the same period in 2013 in response to a planned turnaround during the three months ended September 30, 2014 and higher expenses of $11 million related to plant maintenance also contributed to decreased operating profit.
These decreases were partially offset by higher volume and lower net periodic benefit cost of $38 million for the year ended December 31, 2014 compared to the same period in 2013.
Operating profit also benefited from an increase of $12 million from Other (charges) gains, net for the year ended December 31, 2014 compared to the same period in 2013.
The positive impact of Other (charges) gains, net primarily reflects a decrease in costs associated with the relocation and expansion of our German POM operations.
Equity in net earnings (loss) of affiliates increased $13 million for the year ended December 31, 2014 compared to the same period in 2013 primarily due to an increase in equity investment earnings of $13 million from our Polyplastics strategic
facility continue to have a maturity date of October 2016.
In addition, the maturity date of the Company's revolving credit facility was extended to October 2018 and the facility was increased to $900 million from $600 million.
Accordingly, the Amended Credit Agreement consists of the Term C-2 loan facility, the Term C-3 loan facility and a $900 million revolving credit facility.
Net deferred financing costs are as follows:
## Table 2 ##
(1) Relates to the issuance of the 4.625% Notes.
(2) Relates to the $400 million prepayment of the Term C loan facility with proceeds from the 4.625% Notes.
(3) Relates to the September 2013 amendment to the Celanese US existing senior secured credit facilities to reduce the interest rates payable in connection with certain borrowings thereby creating the Term C-2 loan facility due 2016.
(4) Includes $6 million related to the issuance of the 3.250% Notes and $4 million related to the September 24, 2014 amendment to the Celanese US existing senior secured credit facilities.
(5) Includes $4 million related to the 6.625% Notes redemption and $1 million related to the Term C-2 loan facility conversion.
As of December 31, 2014, the margin for borrowings under the Term C-2 loan facility was 2.0% above the Euro Interbank Offered Rate ("EURIBOR") and the margin for borrowings under the Term C-3 loan facility was 2.25% above LIBOR (for US dollars) and 2.25% above EURIBOR (for Euros), as applicable.
As of December 31, 2014, the margin for borrowings under the revolving credit facility was 1.5% above LIBOR.
The margin for borrowings under the revolving credit facility is subject to increase or decrease in certain circumstances based on changes in the corporate credit ratings of Celanese or Celanese US.
Term loan borrowings under the Amended Credit Agreement are subject to amortization at 1% of the initial principal amount per annum, payable quarterly.
In addition, the Company pays quarterly commitment fees on the unused portion of the revolving credit facility of 0.25% per annum.
The Amended Credit Agreement is guaranteed by Celanese and certain domestic subsidiaries of Celanese US and is secured by a lien on substantially all assets of Celanese US and such guarantors, subject to certain agreed exceptions (including for certain real property and certain shares of foreign subsidiaries), pursuant to the Guarantee and Collateral Agreement, dated April 2, 2007.
As a condition to borrowing funds or requesting letters of credit be issued under the revolving credit facility, the Company's first lien senior secured leverage ratio (as calculated as of the last day of the most recent fiscal quarter for which financial statements have been delivered under the revolving facility) cannot exceed the threshold as specified below.
Further, the Company's first lien senior secured leverage ratio must be maintained at or below that threshold while any amounts are outstanding under the revolving credit facility

Tables referenced above, in order (Table 0 first):
<table><tr><td></td><td colspan="3">Year Ended December 31,</td></tr><tr><td></td><td>2014</td><td>2013</td><td>2012</td></tr><tr><td></td><td colspan="3">(In $ millions)</td></tr><tr><td>Employee termination benefits (Note 4)</td><td>-7</td><td>-23</td><td>-6</td></tr><tr><td>Kelsterbach plant relocation (Note 28)</td><td>—</td><td>-13</td><td>-7</td></tr><tr><td>Plumbing actions</td><td>—</td><td>—</td><td>5</td></tr><tr><td>Asset impairments</td><td>—</td><td>-81</td><td>-8</td></tr><tr><td>Plant/office closures (Note 4)</td><td>2</td><td>-33</td><td>—</td></tr><tr><td>Commercial disputes</td><td>11</td><td>-8</td><td>2</td></tr><tr><td>Other</td><td>9</td><td>—</td><td>—</td></tr><tr><td>Total</td><td>15</td><td>-158</td><td>-14</td></tr></table>
<table><tr><td></td><td colspan="2">Year EndedDecember 31,</td><td></td><td colspan="2">Year EndedDecember 31,</td><td></td></tr><tr><td></td><td>2014</td><td>2013</td><td>Change</td><td>2013</td><td>2012</td><td>Change</td></tr><tr><td></td><td colspan="6">(In $ millions, except percentages)</td></tr><tr><td>Net sales</td><td>1,459</td><td>1,352</td><td>107</td><td>1,352</td><td>1,261</td><td>91</td></tr><tr><td>Net Sales Variance</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Volume</td><td>9%</td><td></td><td></td><td>5%</td><td></td><td></td></tr><tr><td>Price</td><td>-1%</td><td></td><td></td><td>1%</td><td></td><td></td></tr><tr><td>Currency</td><td>—%</td><td></td><td></td><td>1%</td><td></td><td></td></tr><tr><td>Other</td><td>—%</td><td></td><td></td><td>—%</td><td></td><td></td></tr><tr><td>Other (charges) gains, net</td><td>-1</td><td>-13</td><td>12</td><td>-13</td><td>-2</td><td>-11</td></tr><tr><td>Operating profit (loss)</td><td>221</td><td>904</td><td>-683</td><td>904</td><td>95</td><td>809</td></tr><tr><td>Operating margin</td><td>15.1%</td><td>66.9%</td><td></td><td>66.9%</td><td>7.5%</td><td></td></tr><tr><td>Equity in net earnings (loss) of affiliates</td><td>161</td><td>148</td><td>13</td><td>148</td><td>190</td><td>-42</td></tr><tr><td>Depreciation and amortization</td><td>106</td><td>110</td><td>-4</td><td>110</td><td>113</td><td>-3</td></tr></table>
<table><tr><td></td><td>Net Deferred Financing Costs (In $ millions)</td></tr><tr><td>As of December 31, 2011</td><td>28</td></tr><tr><td>Financing costs deferred<sup>-1</sup></td><td>8</td></tr><tr><td>Accelerated amortization due to refinancing activity<sup>-2</sup></td><td>-1</td></tr><tr><td>Amortization</td><td>-5</td></tr><tr><td>As of December 31, 2012</td><td>30</td></tr><tr><td>Financing costs deferred<sup>-3</sup></td><td>2</td></tr><tr><td>Accelerated amortization due to refinancing activity</td><td>—</td></tr><tr><td>Amortization</td><td>-5</td></tr><tr><td>As of December 31, 2013</td><td>27</td></tr><tr><td>Financing costs deferred<sup>-4</sup></td><td>10</td></tr><tr><td>Accelerated amortization due to refinancing activity<sup>-5</sup></td><td>-5</td></tr><tr><td>Amortization</td><td>-5</td></tr><tr><td>As of December 31, 2014</td><td>27</td></tr></table>

Question: how much of the 2013 amortization expense is due to the term c-2 loan facility conversion?
Answer: 0.2
Reasoning program: divide(1,const_5)